Topiramate [‘Topamax’; McNeil] is a new antiepileptic drug (AED) that is currently indicated as add-on therapy for adult patients with partial-onset seizures, the most common seizure type. Generally, when a new AED is introduced its use is restricted to adjunctive therapy, but increased clinical experience with the agent may expand the clinical spectrum of patients who may benefit from treatment. The positive results of several clinical trials which examined topiramate use in adults and children with different types of epilepsy seizures were presented at the 51st Annual Meeting of the American Epilepsy Society [Boston, US; December 1997].